Company Insights

VVOS supplier relationships

Explore interactive graphBrowse insights index
VVOS supplier relationship map

Vivos Therapeutics (VVOS): supplier map and commercial posture for investors

Vivos Therapeutics develops and sells non‑invasive and appliance‑based treatment alternatives for sleep‑disordered breathing, monetizing through device sales, licensed diagnostic technology, distribution and reseller agreements, clinical training services, and periodic capital raises that rely on placement agents. The business blends recurring clinical revenue from its network of trained providers with one‑off manufacturing and distribution contracts; investors should evaluate both the revenue mix and the vendor concentration that underpins device delivery and patient diagnostics. For an investor-focused supplier intelligence portal and ongoing monitoring, visit https://nullexposure.com/.

How Vivos monetizes suppliers and why that matters

Vivos’ operating model pairs a proprietary oral appliance therapy and diagnostic ecosystem with third‑party relationships that extend reach and capability. Revenue is generated by selling appliances and diagnostics, licensing third‑party technology (VivoScore), distributing partner hardware, and by professional services — training, billing, and practice management — that lock providers into the Vivos workflow. Capital markets activity, including warrant exercises and media programs, supports working capital and market visibility rather than direct clinical scale.

Key commercial characteristics:

  • Contracting posture: Vivos uses a mix of exclusive distribution agreements, reseller deals, licensing arrangements, and agency engagements for capital raises and media exposure.
  • Concentration and criticality: Manufacturing partners and a growing network of Vivos‑trained dental practices are operationally critical; media and placement agents are commercially useful but not essential to product delivery.
  • Maturity: The company maintains legacy relationships established in FY2021–FY2022 and expanded supplier ties in FY2025–FY2026, indicating a hybrid maturity profile.
  • Capital dependence: Recent warrant exercises used placement agents to raise working capital, signaling reliance on equity financing to fund near‑term growth.

A practical investor takeaway: assess supplier continuity (manufacturing & diagnostics) and the economics of reseller or distribution deals when modeling revenue stability. For ongoing supplier and partner tracking, explore https://nullexposure.com/.

The supplier and partner map — every public relationship you need to know

Below are the relationships disclosed across the collected reports, each summarized in plain English with source context.

H.C. Wainwright & Co.

Vivos engaged H.C. Wainwright & Co. as the exclusive placement agent for a warrant exercise that raised approximately $4.64 million in gross proceeds in January 2026, a capital‑market action used to fund operations. This is documented in GlobeNewswire/ManilaTimes and QuiverQuant news releases in January 2026.

New to The Street

Vivos signed a 12‑part media series with New to The Street in FY2026 to increase national visibility and investor outreach; the agreement was announced via AccessNewswire and Newswire in 2026 and was amplified by a Bloomberg Television broadcast mention. The program is a marketing and investor relations channel rather than a clinical supplier.

MyoCorrect LLC

Vivos acquired certain assets from MyoCorrect LLC and entered related agreements to launch a myofunctional therapy product line in FY2021, integrating those assets into its therapeutic offering, according to SleepReviewMag coverage referencing the acquisition and product launch.

GM Instruments Ltd

Vivos entered an exclusive U.S./Canadian distribution agreement for GM Instruments’ NR6 Rhinomanometer in FY2022, enabling Vivos to offer an FDA‑approved nasal airflow diagnostic tool to its clinical channels (OrthodonticProductsOnline report, FY2022).

MyCardio, LLC d/b/a SleepImage

Vivos brought VivoScore to market under a licensing, distribution, and marketing agreement with MyCardio/SleepImage in FY2021, providing a third‑party powered home sleep testing diagnostic for patients (SleepReviewMag and a 2021 GlobeNewswire release).

SleepImage (separate mentions)

SleepImage is referenced as the diagnostic technology powering VivoScore and as an integrated element of Vivos’ clinical ecosystem and training center materials in FY2021, per GlobeNewswire and SleepReviewMag reporting.

SoundHealth

In FY2026 Vivos agreed to resell SoundHealth wearables (including CT‑accurate facial scanning and voice biomarker capabilities), using those technologies to screen and monitor patients and to distribute devices through Vivos’ clinical channels, as reported by HitConsultant and Intellectia in early 2026.

MISleep LLC

Vivos executed an agreement with MISleep LLC in July FY2025 for sleep testing and OSA treatment services in the Greater Detroit area, representing a local clinical services partnership to expand testing capacity (InsiderMonkey Q3 2025 earnings call transcript).

Sleep Center of Nevada (SCN)

Vivos reported a $2.2 million increase in OSA sleep testing services driven primarily by Sleep Center of Nevada and launched treatment centers at two SCN Las Vegas locations, demonstrating a revenue‑generating provider partnership in FY2025 (InsiderMonkey Q3 2025 transcript).

Institute for Craniofacial Sleep Medicine

The Institute is part of Vivos’ educational and clinical ecosystem, delivering extensive clinical training and integration with Vivos software, services, and multidisciplinary provider collaboration described in SleepReviewMag and the company’s 2021 announcements.

KCSA Strategic Communications

KCSA served as media relations contact in the 2021 press materials announcing Vivos’ international training center and related corporate communications, per the 2021 GlobeNewswire release; this relationship reflects outsourced PR support rather than clinical supply.

What the supplier picture implies for risk and upside

  • Manufacturing is mission‑critical. The company explicitly uses third‑party contract manufacturers and labs to produce patient‑customized appliances under Vivos’ designs and instructions; continuity of those manufacturing arrangements is essential to revenue delivery. This is a company‑level signal drawn from filing excerpts.
  • Distribution and reseller deals extend scale but transfer execution risk. Exclusive distributors (GM Instruments) and reseller partners (SoundHealth) accelerate market access while creating dependency on partner sales execution.
  • Diagnostic licensing is strategic. The SleepImage/VivoScore relationship reduces R&D burden and accelerates product availability, but it also creates third‑party operational dependencies for HST diagnostics.
  • Capital markets partnerships matter. Use of placement agents like H.C. Wainwright for warrant exercises underlines near‑term funding reliance and the importance of continued investor relations programs.

Key investor actions: evaluate counterparty continuity for manufacturing, track regional provider rollouts (SCN, MISleep) for repeatable revenue, and monitor capital raises that use placement agents for dilution risk.

For a consolidated view of these supplier exposures and ongoing alerts, visit https://nullexposure.com/.

Bottom line and next steps

Vivos’ commercial model combines device manufacturing via third‑party contractors, diagnostic licensing, and distribution/reseller partnerships to scale clinical adoption while relying on investor communications and capital raises to fund growth. Assess supplier continuity, partner sales execution, and capital‑raising cadence when building financial scenarios.

If you are evaluating exposure to VVOS or managing supplier risk in healthcare portfolios, get ongoing supplier intelligence and alerts at https://nullexposure.com/.